Experiences and management needs of endocrine therapy-related symptoms in patients with breast cancer: a systematic review and qualitative evidence synthesis protocol Authors: Lijie Wang, Tao Wei, Jiahui Liu, Siyi Peng, Jiejun Chen, Meihong Hu, Xuying Li Published: 2023 ABSTRACT AbstractIntroductionPatients with breast cancer and endocrine therapy-related symptoms often experience pain, self-denial, anxiety, fear of recurrence and despair, which can be extremely physically and psychologically traumatising for the patients. Failure to receive effective support and management reduces adherence to medications, leading to a higher risk of relapse and mortality. Clearly, it is paramount to identify what support these patients may need and how to meet their symptom management needs. This paper outlines a protocol to synthesise qualitative evidence on endocrine therapy symptom experiences, management expectations and preferences of patients with breast cancer.Methods and analysisThe following databases were searched in November 2023 with no date restriction applied: The Cochrane Library, PubMed, Embase, Web of Science, Scopus, CINAHL and OpenGrey. Published studies on qualitative or mixed-method on symptom experiences and management needs during endocrine therapy in patients with breast cancer will be retrieved. We will also search for reference lists and perform a forward citation search. Before inclusion in this review, two reviewers will independently apply the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Qualitative Research to ensure methodological validity. Any disagreements regarding the evaluation of the articles will be resolved through discussion with or by a third reviewer. Data will be extracted using the standardised data extraction tool EndNote20 for unified management, assessment, and review of information. The common sense model of self-regulation will guide data extraction and synthesis. The final synthesised findings will be graded according to the GRADE-CERQual approach to establish confidence.Ethics and disseminationThis systematic review addressed previously published studies without personally identifiable participant information. Ethical approval from the research committee was not required. The findings of this systematic review will be disseminated to various key stakeholders and published in peer-reviewed journals.PROSPERO registration numberCRD42023406987Keywords: breast tumours, systematic review, qualitative research, patients, nursing care Strengths and limitations of this study This study incorporated the literature from multidisciplinary databases and grey literature to maximise data diversity and comprehensiveness. This study incorporated the literature from multidisciplinary databases and grey literature to maximise data diversity and comprehensiveness. Another major strength of this review is that it strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and used standard quality assessment tools. Another major strength of this review is that it strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and used standard quality assessment tools. Our study will be limited by the exclusion of non-English studies, which precluded the extrapolation of the findings to non-English speaking countries or minorities. Our study will be limited by the exclusion of non-English studies, which precluded the extrapolation of the findings to non-English speaking countries or minorities. Introduction According to the latest global cancer data, new cases of breast cancer have reached 2.26 million, making it the most common cancer globally.1 Approximately three-quarters of patients with breast cancer are oestrogen receptor-positive.2 The 2022 National Comprehensive Cancer Network breast cancer treatment guidelines recommend at least 5 years of adjuvant endocrine therapy for patients with oestrogen receptor-positive breast cancer, reducing the proportion of recurrence and mortality by approximately 40%.3 However, symptoms associated with long-term use of medications affect compliance and significantly reduce the quality of life of patients with breast cancer, leading to poor treatment outcomes and higher healthcare costs, which can increase the risk of recurrence and mortality.4–6 Musculoskeletal and joint symptoms are prevalent as adverse effects, with joint pain occurring in as many as 45.9% of cases. Women with joint pain often report feelings of ageing, increasing with intense joint pain, leading to an approximately 70% increased risk of non-compliance with endocrine therapy (ET).7–9 Fatigue was second only to musculoskeletal symptoms as a patient-reported reason for discontinuing ET.10 Approximately 40% of patients with breast cancer treated with ET experienced severe fatigue and recovery fatigue, with women showing substantial reductions in average daytime activity and increases in total sleep duration.11 Sexual dysfunction is an essential indicator of quality of life in cancer survivors.12 Reproductive symptoms are common in ET in early-stage breast cancer. However, many patients are reluctant to report these symptoms or seek help, resulting in low libido and sexual dysfunction, which ultimately affects their family life.13 14 Despite the prevalence of these symptoms, there is a lack of consensus on how best to manage them, and patient experiences and perspectives on these side effects are unclear. Lifestyle and psychosocial factors contribute to ET-related symptoms.15–17 Patients with breast cancer and symptoms related to ET often experience pain, self-denial, anxiety, fear of recurrence and despair.14 Different symptoms require additional intervention guidance, whereas sexual dysfunction requires medical institutions to provide medication, partner support and psychological guidance. Poor social support has a particularly negative impact on the psychological aspects of the patient, making it difficult to maintain the patient’s behavioural change.12 Therefore, it is crucial to provide support to patients with breast cancer undergoing ET and to address their needs. Due to the consequences of ET-related symptoms in patients with breast cancer, intervention programmes have been developed for the treatment of the symptoms to improve health outcomes. Current interventions include exercise instruction,18 health education,19 20 medication,21 22 psychological intervention23 and Chinese medicine.24 25 Despite the development of interventions for breast cancer therapy-related symptoms, the experience and management needs for symptom management are unclear. Patients who receive ET often express dissatisfaction with their healthcare. They feel that their healthcare providers neither adequately address their symptoms and psychosocial concerns nor do they provide adequate health education on endocrine-related symptoms and treatment options.26 27 However, self-management is fraught with challenges and patients often struggle to receive practical advice. Moreover, to provide patient-centred care, a comprehensive understanding of the symptom experience and management needs of the patients during ET is needed. By better addressing a person’s beliefs and needs, patient-centred care can identify practical coping strategies for patients with breast cancer who experience side effects.28 29 We identified four systematic reviews,30–33 three of which examined factors that influence the experience and adherence to breast cancer treatment. However, these reviews have a broad scope. They considered multiple patient-related factors that influence adherence and persistence. Although these studies provide valuable insights into the lived experiences of ET use, further qualitative work must be conducted to explore the critical reasons for non-adherence. Another systematic review investigated the impact of side effects on adherence to ET in patients with breast cancer. The focus of this study differs from that of the present review in that it focused primarily on adherence to treatment, while the present study focused on the symptom experience and management needs of patients with breast cancer during ET. Their research methodology and analytical framework may differ from those used in this study. This review examined the symptom experiences and management needs of patients with breast cancer undergoing ET. It focuses on the challenges they face, such as physical pain, fatigue, sexual dysfunction and related symptoms, while also exploring effective symptom management strategies from a patient-centred perspective. This review aimed to better understand the patients’ experiences, views, challenges, beliefs and needs regarding ET-related symptoms guided by Self-Regulation Common Sense Model (CSM). It can help control symptoms during ET and provide adequate care and health guidance to improve quality of life and adherence to medications in these patients. Methods Qualitative data will be collected and analysed to explore and summarise the patients’ symptom experiences and management needs during ET to address research questions related to what they experienced, how they responded effectively, and what their needs were for symptom management. Recommendations for the proposed syntheses are provided within the initial scope of the literature search. Our study protocol was registered with PROSPERO and followed the PRISMA-P checklist for reporting systematic reviews and meta-analysis protocols. Additionally, we use the ENTREQ checklist (see online supplemental appendix 1) to enhance transparency in reporting the synthesis of qualitative research when applicable.34 35 bmjopen-2023-073915supp001.pdf Inclusion criteria Types of studies This review will consider qualitative and mixed-methods studies, including, but not limited to, designs such as phenomenology, grounded theory, ethnography and feminist research. Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Phenomenon of interest We will include studies that describe the experiences and management needs of patients with breast cancer with symptoms related to ET. These symptoms will include symptoms that patients find most troublesome during ET, such as joint and muscle pain, fatigue, sexual dysfunction, and menopause-like symptoms. Search strategy The search strategy will combine key search and indexed terms with Boolean operators related to qualitative research. An initial limited search will be performed on PubMed, analysing the MeSH terms included in the titles and abstracts and indexing terms used to describe the articles. It will provide information for developing search strategies tailored to each database source. A second complete search will be performed using all identified keywords and indexing entries in all relevant databases. Reference lists of all original studies identified will be examined for additional studies relevant to this review. Previously published studies in English and Chinese will be considered for inclusion in the database. A comprehensive search strategy has been completed (online supplemental appendix 2). bmjopen-2023-073915supp002.pdf Information sources included the Cochrane Library, PubMed, Embase, Web of Science, Scopus and CINAHL. The search for grey literature will include OpenGrey. Study selection All searched studies will be collated and uploaded to EndNote 20. Duplicate studies will be excluded from the analysis. Two independent reviewers (WL and HM) will screen the titles and abstracts of articles based on inclusion criteria. Studies identified as potentially meeting the criteria or without an abstract will have their full text retrieved. Two independent reviewers (WL and HM) will retrieve and evaluate the full texts of selected citations that meet the inclusion criteria. Full texts that do not meet our inclusion criteria will be excluded and the reasons for exclusion will be included as an appendix in the final systematic review report. The included studies will undergo a rigorous screening process, and any discrepancies between the two evaluators will be resolved through discussion. A third reviewer (LJ) will be involved if no consensus is reached. Assessment of methodological quality The selected qualitative articles will be evaluated by two independent reviewers (WL and HM) using the 10-item checklist of the JBI Qualitative Assessment and Review Instrument to determine their methodological validity before inclusion in the review.36 It has been found to be more consistent and sensitive in evaluating its effectiveness than other commonly used tools. The evaluation criteria included the methodology and philosophical perspective of the study, research objectives, data collection methods, data analysis, interpretation of results, whether there are statements about the researcher’s influence on the study, representativeness of participants, and ethical aspects. All items will be evaluated using ‘yes’, ‘no’ and ‘unclear.’ A summary of the evaluation items is shown in figure 1. The scores for these 10 items were similar to quantitative measures, with low scores of ≤6, medium scores of 7–8 and high scores of 9–10. References with medium or high ratings will be included. Any discrepancies will be resolved by agreement or discussion with a third reviewer (LJ). Studies with medium or high ratings will be included and data will be extracted, synthesised and reflected in the results and conclusions of this systematic review. The low-quality literature will also be reported. Joanna Briggs Institute quality appraisal tool. Data extraction We will create a standardised data extraction table to collect relevant qualitative data from the included studies. We will extract specific details (figure 2) regarding the first author, publication year, geographic location (country or region), participants, research methods and detailed study objectives related to the phenomena of interest (ie, experiences and management needs of the patients with ET-related symptoms) relevant to our review question, theoretical frameworks used in data collection and analysis, and immediate results (themes or subthemes). Two reviewers (WL and HM) will independently extract data from the articles. Disagreements will be resolved by consensus or by a third reviewer (LJ). Data extraction tool to include all the results and findings sections of each included study. We will use CSM to guide the extraction of studies exploring the patients’ experiences, expectations and needs regarding symptoms and their management during ET.37 38 The CSM framework will guide data extraction and coding, including (1) identity beliefs, labels and/or symptoms associated with endocrine-related symptoms or experiences of receiving care for them; (2) timeline beliefs: expected duration of endocrine-related symptoms and temporal nature of endocrine-related symptoms; (3) consequence beliefs: physical, psychological, social and cognitive impact; (4) cause beliefs: what causes symptoms and flare-ups; and (5) control beliefs: how well one can control their endocrine-related symptoms or expectations about care. These components will be used to explore patients' experiences and coping strategies with ET-related symptoms and to provide information on improving symptom management and promoting patients’ quality of life. Data synthesis Framework synthesis uses an a priori framework to guide the deductive and structured data extraction and synthesis approach. We also chose the framework synthesis because it accommodates different qualitative studies and produces review findings. On completion of the data extraction according to the CSM domains, two independent reviewers will compare and discuss their data coding to ensure that their analysis is supported by the results of the primary studies and is consistent with our review objectives. The findings of the framework synthesis will be described in the text and tables. Assessment of confidence in the review findings We will apply the Confidence in the Evidence from Reviews of Qualitative research (GRADE-CERQual) approach to assess (and report) our confidence in the results of this systematic review.39 40 Individual review findings are the output of qualitative evidence synthesis (eg, themes and subthemes).41 The CERQual process is used to analyse the level of confidence or trust in the value and level of evidence of each synthesised finding (figure 3). The CERQual methodology comprises four components as follows: Summary of qualitative findings. Methodological limitations of the individual studies contributing to a finding, Methodological limitations of the individual studies contributing to a finding, Relevance of individual studies to the review question. Relevance of individual studies to the review question. Coherence of the findings across individual studies. Coherence of the findings across individual studies. Adequacy of the data supporting a finding. Adequacy of the data supporting a finding. It will be an iterative process driven by discussions within review teams. Confidence levels will be rated as high, medium, low or very low. We will report the results of our review and CERQual assessment in a tabular form to ensure clarity and transparency. Our planned procedure for data extraction through evidence quality assessment is shown in figure 4. Flow diagram of the processes for our planned qualitative evidence synthesis using a framework approach. Reflexivity To address the potential for bias—the potential for the perspectives and experiences of our review team to unduly influence the subjective nature of qualitative research—we will engage in reflexive exercises. Our review team included nurses, physicians and systematically trained researchers. Throughout the review process, team members’ biases will be inventoried, discussed and considered when making critical decisions about review and analysis. Discussion Patients with breast cancer who undergo ET often experience symptoms, such as bone and joint pain, fatigue and sexual dysfunction that, if not treated promptly with effective management and social support, can seriously affect their quality of life and adherence to medications and increase psychological distress. Although many interventions have been developed to address symptoms associated with breast cancer treatment, the negative beliefs of patients about their symptoms and their dissatisfaction with their healthcare providers have prevented them from receiving effective interventions. To improve the management of ET-related symptoms in patients with breast cancer, we need a comprehensive understanding of how the patients perceive their health problems and care during ET. This systematic review will identify the symptom experiences of patients with breast cancer during ET and integrate these findings to fully understand their difficulties and needs. The specific symptom experiences of the patients can provide information on healthcare, personalised care and education for these patients. Improving care measures will promote the health of these patients and alleviate their healthcare burden. Supplementary Material Reviewer comments Author's manuscript Footnotes Correction notice: This article has been corrected since it was first published. The funding has been updated. Contributors: All authors contributed to this study. LW, TW, JL, SP, JC, MH and XL planned and designed the study and protocol. LW and JH drafted the protocol manuscript with the assistance of TW, SP, MH, CJ and XL. All authors have read and approved the final manuscript. All authors approved the publication of the protocol. Funding: The Scientific Research Project of Hunan Provincial Health Commission (grant number B202314057777, 2023), the Scientific Research Project of Hunan Provincial Health Commission (grant number 202218015813, 2022), and the Scientific research project of Chinese Nursing Association (grant number ZHKY202106, 2022). Competing interests: None declared. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Provenance and peer review: Not commissioned; externally peer reviewed. Supplemental material: This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. Ethics statements Patient consent for publication Not applicable. References Associated Data Supplementary Materials bmjopen-2023-073915supp001.pdf bmjopen-2023-073915supp002.pdf Reviewer comments Author's manuscript